A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment | Orphanet Journal of Rare Diseases
Frontiers | Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT): A Protocol to Address Clinical Trial Readiness in CMT1A
Table 1 from Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies | Semantic Scholar
A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment | Orphanet Journal of Rare Diseases
PDF) Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness | Catharina Faber - Academia.edu
A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. - Abstract - Europe PMC
Frontiers | Temporal Dispersion and Duration of the Distal Compound Muscle Action Potential Do Not Distinguish Diabetic Sensorimotor Polyneuropathy From Chronic Inflammatory Demyelinating Polyneuropathy
Table 4 from Residual disability 10years after falling ill in Guillain–Barré syndrome: A prospective follow-up study | Semantic Scholar
Trial design and outcomes for inherited neuropathy studies D. Pareyson IRCCS Foundation C.Besta Neurological Institute Milan, Italy MSG Meeting, Buffalo, - ppt download
Level of mobility and overall neuropathy limitation score pretreatment... | Download Scientific Diagram
PDF) A modified peripheral neuropathy scale: The Overall Neuropathy Limitations Scale
PDF] Clinical heterogeneity, diagnostic features, outcomes of Guillain-Barré syndrome spectrum disorders: an analysis of IGOS UK data | Semantic Scholar
Clinimetric properties of a walking scale in peripheral neuropathy | Journal of Neurology, Neurosurgery & Psychiatry